Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Solutions

    Solutions

    Our solutions span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Solutions
    Clinical & Scientific OperationsConsultingEarly ClinicalLaboratoriesLanguage ServicesMedical ImagingSite & Patient Solutions Strategic SolutionsTechnologies
    End-to-end services, operational model and technology to deliver customised solutions.
    Decentralised Clinical Trial Solutions

    End-to-end services, operational model and technology to deliver customised solutions.

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.
    Real World Intelligence®

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment and Public HealthMedical DevicePharmaceuticals
    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    2-6 June 2023
    ASCO 2023 conference

    2-6 June 2023

    27 June 2023
    Webinar: Minimising the impact of cross-cultural differences in COA translations

    27 June 2023

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyHealthcare IntelligenceICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON CARES is our commitment to making a positive impact on our people, environment and our community.
    Environmental, Social and Governance

    ICON CARES is our commitment to making a positive impact on our people, environment and our community.

    Clinical Research. Evolved.
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 13 December 2022

    ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others

    ICON finishes the second half of 2022 with an impressive line-up of awards that commend its healthcare intelligence work and status as an employer of choice.

  • 23 November 2022

    ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference

    ICON plc announced today that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022.

  • 2 November 2022

    ICON Reports Third Quarter 2022 Results

    Quarter 3 revenue of $1,942.4 million representing an increase of 3.9% on prior year adjusted revenue and 7.4% on a constant currency organic basis.

  • 6 October 2022

    ICON selected by BARDA to conduct anthrax vaccine clinical trial

    ICON plc announces that it has been selected by BARDA, part of the ASPR, in the Department of HHS, to execute an anthrax vaccine clinical trial.

  • 26 September 2022

    ICON plc schedules third quarter 2022 earnings conference call

    ICON plc schedules second quarter 2022 earnings conference call on Wednesday, November 2, 2022.

  • 6 September 2022

    ICON releases its 2021 ESG report

    ICON plc today (6 Sept, 2022) releases its 2021 Environmental, Social and Governance (ESG) Report.

  • 31 August 2022

    ICON plc to Present at the 2022 Wells Fargo Healthcare Conference

    ICON plc announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022. The presentation will be webcast live from 10:25am EDT.

  • 27 July 2022

    ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting

    ICON plc today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 26, 2022 (which resolutions had all been recommended by the Board) were all duly passed by shareholders.

  • 27 July 2022

    ICON Reports Second Quarter 2022 Results

    Quarter 2 revenue of $1,935.2 million representing a year on year increase of 122.1%.

  • 22 June 2022

    ICON establishes university scholarship programme to provide increased opportunities for underrepresented groups to study STEM-related courses

    ICON establishes university scholarship programme to provide increased opportunities for underrepresented groups to study STEM-related courses.

  • 1
  • 2
  • 3
  • 4
  • 5
  • ...
  • 16
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
      • ASCO 2023
      • BioEquity Europe
      • FT US Pharma and Biotech Summit
    • Webinars
    • Workshops
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2023 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies
  • International Transfers

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media